FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Kaijia ZhouTao JiangYanwei LiuZheng ZhaoLijie HuangGuanzhang LiPublished in: BMC neurology (2021)
FXYD2 mRNA expression represents a new independent factor affecting the survival of glioma patients and may serve as an independent prognostic indicator to predict the sensitivity of gliomas to TMZ.